STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans
The FDA, while promising flexibility in approving Baby KJ-type gene editing, still has set standards difficult for a small startup to meet.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.